JP2000109428A - Composition for pharyngeal mucosa - Google Patents
Composition for pharyngeal mucosaInfo
- Publication number
- JP2000109428A JP2000109428A JP10283060A JP28306098A JP2000109428A JP 2000109428 A JP2000109428 A JP 2000109428A JP 10283060 A JP10283060 A JP 10283060A JP 28306098 A JP28306098 A JP 28306098A JP 2000109428 A JP2000109428 A JP 2000109428A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- acid
- pharyngeal mucosa
- polyphenol
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 210000004877 mucosa Anatomy 0.000 title claims description 15
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000645 desinfectant Substances 0.000 claims abstract description 13
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 12
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- -1 decalinium Chemical compound 0.000 claims abstract description 6
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 5
- 229940074391 gallic acid Drugs 0.000 claims abstract description 5
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 4
- ZRVSAJIGCDWADZ-UHFFFAOYSA-N Leucoanthocyanin Natural products OCC1OC(CC(O)C1O)OC2C(O)c3c(O)cc(O)cc3OC2c4ccc(O)c(O)c4 ZRVSAJIGCDWADZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 4
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004830 cetylpyridinium Drugs 0.000 claims abstract description 4
- 229960003260 chlorhexidine Drugs 0.000 claims abstract description 4
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 4
- 229920002258 tannic acid Polymers 0.000 claims abstract description 4
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 4
- 229940033123 tannic acid Drugs 0.000 claims abstract description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims abstract description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims abstract description 3
- SBZWTSHAFILOTE-SOUVJXGZSA-N (2R,3S,4S)-leucocyanidin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3[C@H](O)[C@@H]2O)=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-SOUVJXGZSA-N 0.000 claims abstract description 3
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims abstract description 3
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims abstract description 3
- 229920002079 Ellagic acid Polymers 0.000 claims abstract description 3
- HMXJLDJMSRBOCV-UHFFFAOYSA-N Leucocyanidin Natural products OC1C(OC2C(O)C(Oc3cc(O)cc(O)c23)c4ccc(O)c(O)c4)c5c(O)cc(O)cc5OC1c6ccc(O)c(O)c6 HMXJLDJMSRBOCV-UHFFFAOYSA-N 0.000 claims abstract description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000005487 catechin Nutrition 0.000 claims abstract description 3
- 229950001002 cianidanol Drugs 0.000 claims abstract description 3
- 235000004132 ellagic acid Nutrition 0.000 claims abstract description 3
- 229960002852 ellagic acid Drugs 0.000 claims abstract description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000012734 epicatechin Nutrition 0.000 claims abstract description 3
- SBZWTSHAFILOTE-UHFFFAOYSA-N leucocianidol Natural products OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940086558 leucocyanidin Drugs 0.000 claims abstract description 3
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 210000003800 pharynx Anatomy 0.000 claims description 9
- 229920002770 condensed tannin Polymers 0.000 claims description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 4
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 claims description 4
- 229920001461 hydrolysable tannin Polymers 0.000 claims description 4
- JEUXGAUBSWADEA-MRVWCRGKSA-N melacacidin Chemical compound C1([C@H]2OC3=C(O)C(O)=CC=C3[C@@H](O)[C@H]2O)=CC=C(O)C(O)=C1 JEUXGAUBSWADEA-MRVWCRGKSA-N 0.000 claims description 4
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 3
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 3
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims description 2
- 241000238557 Decapoda Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- JWCBMQQZRJYFKV-UHFFFAOYSA-O melacacinidin Natural products C1=C(O)C(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C=CC(O)=C2O JWCBMQQZRJYFKV-UHFFFAOYSA-O 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- FLZGFQFYDGHWLR-UHFFFAOYSA-N luteic acid Chemical compound O1C(=O)C2=CC(O)=C(O)C(O)=C2C2=C1C(O)=C(O)C=C2C(=O)O FLZGFQFYDGHWLR-UHFFFAOYSA-N 0.000 abstract 2
- 229920001864 tannin Polymers 0.000 abstract 2
- 235000018553 tannin Nutrition 0.000 abstract 2
- 239000001648 tannin Substances 0.000 abstract 2
- 229920001884 Luteic acid Polymers 0.000 abstract 1
- 230000005494 condensation Effects 0.000 abstract 1
- 238000009833 condensation Methods 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 230000002070 germicidal effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 229940124584 antitussives Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 206010013082 Discomfort Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 208000023409 throat pain Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101150000715 DA18 gene Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- FZHLWVUAICIIPW-UHFFFAOYSA-M sodium gallate Chemical compound [Na+].OC1=CC(C([O-])=O)=CC(O)=C1O FZHLWVUAICIIPW-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【従来の技術】ポリフェノール類は、茶の中に多く含ま
れていることが知られており、茶中のポリフェノール類
が各種のウイルスや細菌の感染を防御することが知られ
ている（特開平３−１０６８２０号、特開平３−２４６
２２７号）。2. Description of the Related Art It is known that tea contains a large amount of polyphenols, and it is known that the polyphenols in tea protect against infections of various viruses and bacteria (Japanese Patent Laid-Open Publication No. HEI 9 (1994) -197686). 3-106820, JP-A-3-246
227).
【０００２】咽頭部の違和感を感じる場合の代表的な例
は、上気道を中心とする局所炎症性症状に倦怠感等の種
々の全身症状を伴う疾患である風邪症候群等のウイルス
性の呼吸器感染症に感染した場合である。上気道の炎症
症状である咽頭部の充血や腫れは、風邪症候群の罹患の
際に高い頻度で発現する症状であり、この症状の自覚症
状である咽頭部の疼痛症状等の違和感の除去・緩解が対
症療法の中心的役割を占めている。[0002] A typical example of a case where the pharynx is uncomfortable is a viral respiratory tract such as a cold syndrome which is a disease accompanied by various systemic symptoms such as malaise as well as local inflammatory symptoms mainly in the upper respiratory tract. Infectious disease. Pharyngeal hyperemia or swelling, which is an inflammatory symptom of the upper respiratory tract, is a symptom that frequently occurs when a person has the cold syndrome, and removal / remission of discomfort such as pharyngeal pain, which is a subjective symptom of this symptom. Plays a central role in symptomatic treatment.
【０００３】この他、アレルギーや大気汚染等による咽
頭粘膜の刺激が粘膜表面を傷害し、このことに伴う咽頭
部の充血や腫れも違和感として捉えられることが知られ
ているが、対処法は対症療法が主体となっている。[0003] In addition, it is known that irritation of the pharyngeal mucosa due to allergy or air pollution damages the mucosal surface, and consequent redness and swelling of the pharynx can be perceived as uncomfortable. Therapy is the main.
【０００４】対症療法では、一般に殺菌消毒薬、消毒
薬、消炎酵素薬、局所麻酔薬、漢方薬又はヨウ素類を有
効成分としたトローチ剤、ドロップ剤、舐剤、含嗽剤、
ストリーム剤又はスプレー剤等の経口投与剤型で用いる
ことが行われている。[0004] In symptomatic treatments, generally, troches, drops, lozenges, mouthwashes containing bactericidal disinfectants, disinfectants, anti-inflammatory enzymes, local anesthetics, Chinese herbs or iodine as active ingredients,
It has been used in oral dosage forms such as stream or spray.
【０００５】これらの薬剤により、咽頭部の違和感はご
く一時的に緩解するものの、効力、持続時間、利便性等
の諸要素に対し充分に満足できる効果をもった薬剤が得
られておらず、更に、違和感の緩解のためにこれら薬剤
の使用頻度を増やすと副作用発現の危険性を増大させる
という危惧がある。Although these pharyngeal discomforts are temporarily relieved by these drugs, drugs having sufficiently satisfactory effects on various factors such as efficacy, duration, and convenience have not been obtained. Furthermore, there is a concern that increasing the frequency of use of these drugs for relieving discomfort may increase the risk of side effects.
【０００６】また、咽頭部粘膜の腫脹や損傷は、新たな
ウイルス感染や細菌の二次感染や各種アレルゲン、大気
汚染物質の暴露の機会をつくり出し、違和感の重症化や
遷延化、全身症状への拡大に結びつきやすいリスクを負
う。従って、効力、持続時間、利便性及び使用感の優れ
た薬剤の開発が望まれている。[0006] In addition, swelling and damage to the pharyngeal mucosa create new viral infections, secondary bacterial infections, and opportunities for exposure to various allergens and air pollutants, leading to more severe and prolonged discomfort and to general symptoms. Take risks that can easily lead to expansion. Therefore, development of a drug excellent in efficacy, duration, convenience and feeling of use is desired.
【０００７】[0007]
【発明が解決しようとする課題】本発明の目的は、咽頭
部の違和感の除去あるいは軽減を図るため、効力、持続
時間、利便性及び使用感が優れ、特に咽頭部の疼痛症状
（のどの痛み）を著しく低減する咽頭粘膜用組成物を提
供することにある。SUMMARY OF THE INVENTION An object of the present invention is to eliminate or reduce the discomfort of the pharynx, so that its efficacy, duration, convenience and feeling of use are excellent. ) Is to provide a composition for the pharyngeal mucosa which significantly reduces pharyngeal mucosa.
【０００８】[0008]
【課題を解決するための手段】本発明者らは、上述の課
題を解決すべく鋭意研究を重ねた結果、有効成分として
ポリフェノール類と殺菌消毒薬を配合することにより、
咽頭部の違和感、特に疼痛症状（のどの痛み）が著しく
低減されることを見い出した。Means for Solving the Problems The present inventors have made intensive studies to solve the above-mentioned problems, and as a result, by blending polyphenols and a disinfectant as active ingredients,
We have found that the discomfort of the pharynx, especially pain symptoms (throat pain), are significantly reduced.
【０００９】本発明おいて、ポリフェノール類として
は、加水分解型タンニン又は縮合型タンニンが挙げられ
る。また、加水分解型タンニンとしては、タンニン酸、
没食子酸、没食子酸誘導体、ガロイル没食子酸、ルテオ
ン酸、エラジン酸又はこれらの類縁物質並びにこれらの
塩類、また、縮合型タンニンとしては、カテキン、エビ
ガロカテキン、エピカテキン、ロイコアントシアニン、
ロイコシアニジン、メラカシジン、モリサカシジン、ロ
イコアントシアニジン又はこれらの類縁物質並びにこれ
らの塩類が挙げられる。殺菌消毒薬としては、クロルヘ
キシジン、デカリニウム、セチルピリジニウム又はこれ
らの塩類が挙げられる。In the present invention, examples of polyphenols include hydrolyzable tannins and condensed tannins. Further, as the hydrolyzable tannin, tannic acid,
Gallic acid, gallic acid derivatives, galloyl gallic acid, luteonic acid, ellagic acid or analogs thereof and salts thereof, and as the condensed tannin, catechin, shrimp gallocatechin, epicatechin, leucoanthocyanin,
Examples include leucocyanidin, melacacidin, morrisacacidin, leucoanthocyanidin, analogous substances thereof, and salts thereof. Examples of the germicidal disinfectant include chlorhexidine, decalinium, cetylpyridinium, and salts thereof.
【００１０】本発明の咽頭粘膜用組成物は、有効成分と
してポリフェノール類１重量部に対し、殺菌消毒薬０．
００００２５〜０．２重量部であり、好ましくは０．０
０００４〜０．１重量部を配合する。[0010] The composition for pharyngeal mucosa of the present invention contains 1 part by weight of polyphenols as an active ingredient and 0.1% by weight of a germicidal disinfectant.
0.0025 to 0.2 parts by weight, preferably 0.02 to 0.2 parts by weight.
0004 to 0.1 parts by weight are blended.
【００１１】ポリフェノール類の有効配合量は、成人で
一日当たり２５０〜６０００ｍｇであり、好ましくは５
００〜５０００ｍｇである。The effective compounding amount of polyphenols is 250 to 6000 mg per day for adults, preferably 5 to 6000 mg per day.
It is 00-5000 mg.
【００１２】また、殺菌消毒薬の有効配合量は、成人で
一日当たりクロルヘキシジンは１０〜４５ｍｇであり、
好ましくは１５〜３０ｍｇであり、デカリニウムは０．
２〜１．２ｍｇであり、好ましくは０．２５〜１ｍｇで
あり、セチルピリジニウムは１．５〜８ｍｇであり、好
ましくは２〜６ｍｇである。この投薬量は年齢、体重、
病状により適宜増減することができる。The effective amount of the germicidal disinfectant is 10 to 45 mg of chlorhexidine per day for adults.
It is preferably 15 to 30 mg, and the amount of decalinium is 0.1 mg.
It is 2 to 1.2 mg, preferably 0.25 to 1 mg, and cetylpyridinium is 1.5 to 8 mg, preferably 2 to 6 mg. This dosage depends on age, weight,
It can be increased or decreased as appropriate depending on the condition.
【００１３】本発明の咽頭粘膜用組成物は、風邪薬、鎮
咳去痰薬、鼻炎用薬、咽頭用薬、風邪予防薬、口腔内殺
菌用薬、口腔内消炎薬、口臭除去薬等に用いることがで
き、さらに必要により医薬部外品、医療用具等幅広い形
態で用いることができる。The composition for pharyngeal mucosa of the present invention is used for cold medicine, antitussive expectorant, rhinitis medicine, pharyngeal medicine, cold prevention medicine, oral disinfectant, oral antiphlogistic, bad breath remover, etc. It can be used in a wide variety of forms such as quasi-drugs and medical devices as needed.
【００１４】本発明の咽頭粘膜用組成物は、他に必要に
応じて、抗アレルギー薬、解熱鎮痛薬、消炎酵素類、気
管支拡張薬、鎮咳薬、去痰薬、交感神経興奮薬、抗コリ
ン薬、カフェイン類、ビタミン薬、他の生薬類、香料等
の成分を適宜に配合することができる。なお、これらの
成分は単独または相互に混合して用いることができ、通
常は医薬品製造指針(１９９５年版・薬業時報社)に収載
されている一般用医薬品の鎮咳去痰薬の基準及び含嗽
剤、歯科口腔用剤の記載に準拠して配合される。The composition for pharyngeal mucosa of the present invention may further comprise, if necessary, an antiallergic drug, an antipyretic analgesic, an anti-inflammatory enzyme, a bronchodilator, an antitussive, an expectorant, a sympathomimetic, an anticholinergic. Ingredients such as caffeine, vitamins, other crude drugs, and fragrances can be appropriately blended. In addition, these components can be used alone or as a mixture of each other. Usually, the standards for antitussive expectorants and gargles of over-the-counter drugs listed in the Pharmaceutical Manufacturing Guideline (1995 edition, Pharmaceutical Times), It is blended according to the description of the dental oral preparation.
【００１５】本発明の咽頭粘膜用組成物は、常法により
調製することができる。必要に応じて固形剤の場合には
賦形剤、滑沢剤、崩壊剤等を、液剤の場合には界面活性
剤、溶解補助剤、緩衝剤等を使用することができる。ま
た、この他保存剤、香料、色素、甘味剤・嬌味剤、清涼
化剤、着色剤等を使用することができる。The composition for pharyngeal mucosa of the present invention can be prepared by a conventional method. Excipients, lubricants, disintegrating agents and the like can be used in the case of solid preparations, and surfactants, solubilizing agents, buffers and the like can be used in the case of liquid preparations. In addition, other preservatives, flavors, pigments, sweeteners / flavors, fresheners, coloring agents, and the like can be used.
【００１６】[0016]
【発明の効果】有効成分として、ポリフェノール類と殺
菌消毒薬を配合することにより、咽頭部の疼痛症状（の
どの痛み）等をはじめとする幅広い違和感を著しく低減
する咽頭粘膜用組成物が得られた。As described above, a composition for the pharyngeal mucosa can be obtained by blending polyphenols and a germicidal disinfectant as active ingredients, which significantly reduces a wide range of discomforts including pharyngeal pain symptoms (throat pain). Was.
【００１７】[0017]
【実施例】以下、実施例及び試験例を挙げ本発明をさら
に詳しく説明するが、本発明は下記の例に限定されるも
のではない。The present invention will be described in more detail with reference to the following examples and test examples, but the present invention is not limited to the following examples.
【００１８】実施例１ 下記の各成分及び分量を秤量し均一に混合した後、得ら
れた混合粉末を直打法により１剤重量３００ｍｇになる
ように打錠し、トローチ剤８０００個を得た。Example 1 The following components and amounts were weighed and uniformly mixed, and then the resulting mixed powder was tableted to a weight of 300 mg per agent by a direct compression method to obtain 8,000 lozenges. .
【００１９】 タンニン酸 ２０００ｇ 塩酸クロルヘキシジン １５ｇ 塩化リゾチーム ３０ｇ（力価） 乳糖 １７５ｇ 低置換度ヒドロキシプロピルセルロース １５０ｇ ステアリン酸マグネシウム １５ｇ 硬化ヒマシ油 １５ｇ 実施例２ 下記の各成分及び分量を秤量し均一に混合した後、水飴
と練り合わせ舐剤２６００ｇを得た。Tannic acid 2000 g Chlorhexidine hydrochloride 15 g Lysozyme chloride 30 g (titer) Lactose 175 g Low-substituted hydroxypropylcellulose 150 g Magnesium stearate 15 g Hardened castor oil 15 g Example 2 The following components and amounts were weighed and uniformly mixed. Then, 2600 g of syrup and kneaded syrup were obtained.
【００２０】 エピガロカテキン １５００ｇ 塩化セチルピリジニウム ３ｇ 塩化リゾチーム ３０ｇ（力価） 乳糖 １５０ｇ 低置換度ヒドロキシプロピルセルロース １２５ｇ ステアリン酸マグネシウム １６ｇ 水飴 ７７６ｇ 実施例３ 下記の各成分及び分量を秤量し均一に混合した後、精製
水１００ｍｌに溶解し点眼薬を製した。Epigallocatechin 1500 g Cetylpyridinium chloride 3 g Lysozyme chloride 30 g (titer) Lactose 150 g Low-substituted hydroxypropylcellulose 125 g Magnesium stearate 16 g Sugar syrup 776 g Example 3 The following components and amounts were weighed and uniformly mixed. Was dissolved in 100 ml of purified water to prepare eye drops.
【００２１】 没食子酸ナトリウム ４５００ｍｇ 塩化デカリニウム １．５ｍｇ 塩化リゾチーム ４５ｍｇ（力価） 塩酸リドカイン ５００ｍｇ 実施例４ 下記の各成分及び分量を秤量し均一に混合した後、精製
水１００ｍｌに溶解し洗鼻薬を製した。Sodium gallate 4500 mg Decalinium chloride 1.5 mg Lysozyme chloride 45 mg (titer) Lidocaine hydrochloride 500 mg Example 4 The following components and amounts were weighed and uniformly mixed, then dissolved in 100 ml of purified water to prepare a nasal rinse. did.
【００２２】 ロイコアントシアニン ５０００ｍｇ 塩化セチルピリジニウム ６ｍｇ 塩酸リドカイン ５００ｍｇ ｄｌ−メントール ５００ｍｇ 試験例１ 咽頭部違和感に関する検討 ＜試験方法＞下記の表１の処方例により、本発明の被験
薬６種、対照薬６種をストリーム剤として製した。これ
を咽頭部に何らかの違和感を感じる者４８名（１群４
名）に、１日６回３日間使用させ、使用前後の全般的な
使用の印象を比較した。なお、印象は「５点：非常に耐
えられない違和感を感じる」「４点：非常に違和感を感
じる」「３点：違和感を感じる」「２点：軽度の違和感
を感じる」「１点：わずかに違和感を感じる」「０点：
まったく違和感を感じない」の６段階で評価し、２点以
上点数が減った者の人数及び比率で比較した。Leucoanthocyanin 5000 mg Cetylpyridinium chloride 6 mg Lidocaine hydrochloride 500 mg dl-menthol 500 mg Test example 1 Examination of pharyngeal discomfort <Test method> According to the prescription examples shown in Table 1 below, six test drugs of the present invention and six control drugs were used. Was produced as a stream agent. 48 people who felt something uncomfortable in the pharynx (1 group 4
) Was used 6 times a day for 3 days, and the overall impression of use before and after use was compared. The impressions were "5 points: very uncomfortable feeling", "4 points: very uncomfortable", "3 points: feeling uncomfortable", "2 points: slight discomfort", "1 point: slight" Feel uncomfortable "" 0 points:
I did not feel any discomfort at all ", and the comparison was made based on the number and ratio of those who scored 2 or more points reduced.
【００２３】[0023]
【表１】 [Table 1]
【００２４】＜結果＞使用感試験の結果を表２に示す。<Results> Table 2 shows the results of the usability test.
【００２５】この判定において、本発明の被験薬群の方
が対照薬群より優っており、咽頭部の違和感を低減する
ことが示された。In this judgment, it was shown that the test drug group of the present invention is superior to the control drug group and reduces the discomfort of the pharynx.
【００２６】[0026]
【表２】 [Table 2]
フロントページの続き Ｆターム(参考） 4C086 AA01 AA02 BA08 BC17 BC28 GA07 MA02 MA03 MA04 MA09 MA10 MA56 NA05 NA14 ZA34 ZA59 ZC75 4C206 AA01 AA02 DA04 DA18 DB17 HA10 MA02 MA03 MA04 MA13 MA14 MA76 NA05 NA14 ZA34 ZA59 ZC75 Continued on front page F-term (reference) 4C086 AA01 AA02 BA08 BC17 BC28 GA07 MA02 MA03 MA04 MA09 MA10 MA56 NA05 NA14 ZA34 ZA59 ZC75 4C206 AA01 AA02 DA04 DA18 DB17 HA10 MA02 MA03 MA04 MA13 MA14 MA76 NA05 NA14 ZA34 ZA59 ZC75
Claims (5)
咽頭粘膜用組成物1. A composition for pharyngeal mucosa comprising a polyphenol and a disinfectant.
及び縮合型タンニンから選ばれる１種または２種である
請求項１記載の咽頭粘膜用組成物2. The composition for pharyngeal mucosa according to claim 1, wherein the polyphenol is one or two selected from a hydrolyzable tannin and a condensed tannin.
ニウム、セチルピリジニウム及びそれらの塩類から選ば
れる１種または２種以上である請求項１記載の咽頭粘膜
用組成物3. The composition for pharyngeal mucosa according to claim 1, wherein the disinfectant is one or more selected from chlorhexidine, decalinium, cetylpyridinium and salts thereof.
子酸、没食子酸誘導体、ガロイル没食子酸、ルテオン
酸、エラジン酸及びこれらの塩類から選ばれる１種また
は２種である請求項２記載の咽頭粘膜用組成物4. The pharynx according to claim 2, wherein the hydrolyzable tannin is one or two selected from tannic acid, gallic acid, gallic acid derivatives, galloyl gallic acid, luteonic acid, ellagic acid and salts thereof. Mucosal composition
テキン、エピカテキン、ロイコアントシアニン、ロイコ
シアニジン、メラカシジン、モリサカシジン、ロイコア
ントシアニジン及びこれらの塩類から選ばれる１種また
は２種以上である請求項２記載の咽頭粘膜用組成物 【産業上の利用分野】本発明は、咽頭部の違和感を感じ
る際に使用する咽頭粘膜用組成物に関する。詳しくは、
有効成分としてポリフェノール類と殺菌消毒薬を配合す
る咽頭部の違和感を著しく低減する咽頭粘膜用組成物で
ある。5. The condensed tannin is one or more selected from the group consisting of catechin, shrimp gallocatechin, epicatechin, leucoanthocyanin, leucocyanidin, melacacidin, morisacasidin, leucoanthocyanidin and salts thereof. BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for pharyngeal mucosa used when the pharynx is uncomfortable. For more information,
A composition for the pharyngeal mucosa, which significantly reduces discomfort in the pharynx, comprising a polyphenol and a disinfectant as active ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10283060A JP2000109428A (en) | 1998-10-05 | 1998-10-05 | Composition for pharyngeal mucosa |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10283060A JP2000109428A (en) | 1998-10-05 | 1998-10-05 | Composition for pharyngeal mucosa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000109428A true JP2000109428A (en) | 2000-04-18 |
Family
ID=17660693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10283060A Pending JP2000109428A (en) | 1998-10-05 | 1998-10-05 | Composition for pharyngeal mucosa |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000109428A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000212094A (en) * | 1998-11-18 | 2000-08-02 | Takeda Chem Ind Ltd | Pharmaceutical preparation for oral cavity |
| JP2011509270A (en) * | 2008-01-11 | 2011-03-24 | インデナ エッセ ピ ア | Formulations for the treatment of mucositis induced by anti-tumor therapy or immunosuppressive therapy |
| US20110135769A1 (en) * | 2008-06-05 | 2011-06-09 | Indena S.P.A. | Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes |
| WO2011092835A1 (en) * | 2010-01-29 | 2011-08-04 | パナセア ディシンフェクタント カンパニー リミテッド | Antiseptic solution for continuous oral disinfection |
| RU2492862C2 (en) * | 2008-02-22 | 2013-09-20 | Индена С.П.А. | Anti-cancer agents with benzophenanthridine structure and preparations containing them |
-
1998
- 1998-10-05 JP JP10283060A patent/JP2000109428A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000212094A (en) * | 1998-11-18 | 2000-08-02 | Takeda Chem Ind Ltd | Pharmaceutical preparation for oral cavity |
| JP2011509270A (en) * | 2008-01-11 | 2011-03-24 | インデナ エッセ ピ ア | Formulations for the treatment of mucositis induced by anti-tumor therapy or immunosuppressive therapy |
| US8940338B2 (en) * | 2008-01-11 | 2015-01-27 | Indena S.P.A. | Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy |
| RU2492862C2 (en) * | 2008-02-22 | 2013-09-20 | Индена С.П.А. | Anti-cancer agents with benzophenanthridine structure and preparations containing them |
| US20110135769A1 (en) * | 2008-06-05 | 2011-06-09 | Indena S.P.A. | Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes |
| JP2011521982A (en) * | 2008-06-05 | 2011-07-28 | インデナ エッセ ピ ア | Composition for treating upper respiratory tract disease and influenza syndrome |
| US9101604B2 (en) * | 2008-06-05 | 2015-08-11 | Indena S.P.A. | Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes |
| JP2016147914A (en) * | 2008-06-05 | 2016-08-18 | インデナ エッセ ピ ア | Compositions for treatment of disorders of upper respiratory tract and influenza syndromes |
| WO2011092835A1 (en) * | 2010-01-29 | 2011-08-04 | パナセア ディシンフェクタント カンパニー リミテッド | Antiseptic solution for continuous oral disinfection |
| JPWO2011092835A1 (en) * | 2010-01-29 | 2013-05-30 | パナセア ディシンフェクタント カンパニー リミテッド | Long-lasting bactericidal disinfectant |
| JP5673560B2 (en) * | 2010-01-29 | 2015-02-18 | パナセア ディシンフェクタント カンパニー リミテッド | Long-lasting bactericidal disinfectant |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101337578B1 (en) | Mucoadhesive xyloglucan―containing formulations useful in medical devices and in pharmaceutical formulations | |
| US8450339B2 (en) | Compositions for treatment of common cold | |
| EP0506658B1 (en) | Compositions and method for treating painful, inflammatory or allergic disorders | |
| EP1444984B1 (en) | Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes | |
| EP0696190B1 (en) | Nasal aromatic releasing compositions | |
| JP2002212107A (en) | Topical application composition | |
| Sabbah et al. | Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children | |
| Creticos et al. | Intranasal budesonide aqueous pump spray (rhinocort® aqua) for the treatment of seasonal allergic rhinitis | |
| JP2000109428A (en) | Composition for pharyngeal mucosa | |
| NO309965B1 (en) | Oral pharmaceutical anti-cough preparation | |
| JP2002205942A (en) | Composition for topical application | |
| EP0640338A1 (en) | Sodium cromoglycate for the treatment of upper respiratory tract infections | |
| US20170020946A1 (en) | Analgesic compositions and methods of use | |
| KR20200131913A (en) | Pharmaceutical compositions comprising flurbiprofen | |
| US20060216359A1 (en) | Topical preparation for treating ulcerations on the inside of the month | |
| Stübner et al. | Efficacy and Safety of an Oral Formulation of Cetirizine and Prolonged-release Pseudoephedrine versus Xylometazolin Nasal Spray in Nasal Congestion | |
| JP2000327573A (en) | Composition for applying to mucosa | |
| JP2000247873A (en) | Composition for erasing sense of incompatibility at mucosal site | |
| AU2002236141B2 (en) | Method of treatment | |
| JP2001139465A (en) | Composition for pharyngeal mucosa | |
| JP2002241310A (en) | Locally applying composition | |
| JP2002145764A (en) | Composition for pharyngeal mucous membrane | |
| JPH11302189A (en) | Composition for cold | |
| JP2002370977A (en) | Composition for topical application | |
| JP2006008540A (en) | Cold remedy |